research 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
Baricitinib stops hair loss and promotes regrowth in alopecia areata.
Search
for
Sort by
Research
360-390 / 1000+ resultsresearch Comparative Study between The Efficacy and Safety of Topical Immune Therapy with Diphenylcyclopropenone versus Anthralin in The Treatment of Resistant Alopecia Areata
Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
research Teriflunomide: A Once-daily Oral Medication for the Treatment of Relapsing Forms of Multiple Sclerosis
Teriflunomide effectively reduces relapse rates and disease progression in multiple sclerosis but is not safe for use during pregnancy.
research Efficacy of spironolactone as adjunctive therapy to sodium valproate in bipolar‐I disorder: A double‐blind, randomized, placebo‐controlled clinical trial
Spironolactone improved cognitive performance and early sleep quality but not manic symptoms, appetite, or body weight in bipolar disorder when added to sodium valproate.
research Androgen metabolism in hirsute patients treated with cyproterone acetate
Cyproterone acetate effectively reduced hair growth in hirsute patients by lowering androgen levels and altering androgen metabolism.
research Improvement of Recalcitrant Dissecting Cellulitis of the Scalp After a Trial of Upadacitinib
Upadacitinib significantly improved a man's severe scalp condition when other treatments failed.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Cyproterone acetate for severe hirsutism:results of a double‐blind dose‐ranging study*
Cyproterone acetate at 2mg daily is as effective as higher doses for treating excessive hair growth in women.
research Actos, slings, finasteride, and the vaccine compensation solution.
research Effect of 5α-reductase inhibitors on sexual function: New contributions
5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research Thrombotic risk minimization for D iane‐35 and generics
The use of Diane-35 and its generics significantly decreased in the Netherlands.
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research The Off-Label Use of Selective Serotonin Reuptake Inhibitors for Sexual Behavior Management: Risks and Considerations
SSRIs may help manage sexual behavior in dementia patients, but they can cause long-lasting sexual dysfunction.
research Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
Trazodone and chlorpromazine may help treat sexual dysfunction caused by finasteride and SSRIs.
research Trichotillomania as a Manifestation of Dementia
Trichotillomania in dementia may be better treated with dopamine blockers like quetiapine than with SSRIs.
research Alopecia secondary to severe discoid lupus responding to anifrolumab
Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.
research Ponatinib-induced pityriasis rubra pilaris-like adnexal dysmaturation: A case report
Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Patient Considerations when Using Ritlecitinib for Alopecia Areata in Adolescents: Guidance for the Clinicians
Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.
research Targeting neurosteroid synthesis as a therapy for schizophrenia-related alterations induced by early psychosocial stress
A drug improved schizophrenia-like symptoms in stressed rats by changing brain steroid levels.
research Androgen receptor signaling as a new target for intervention in acute myeloid leukemia
Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.
research Hair loss disorders (alopecias)
Ritlecitinib is a new treatment for severe hair loss in people 12 and older.
research A phase 2a trial of brepocitinib for cicatricial alopecia
Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.
research 52243 AH-001: An Emerging Androgen Receptor Degrader Showing Therapeutic Potential in Addressing Androgenetic Alopecia (AGA)
AH-001 could be a safer and more effective treatment for hair loss.
research Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: A systematic review and meta-analysis
Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.
research Association of AR rs6152G/A gene polymorphism with susceptibility to polycystic ovary syndrome in Chinese women
A certain gene variant may increase the risk of polycystic ovary syndrome in Chinese women.
research Association Between 5α-Reductase Inhibitors and Prostate Cancer Mortality
5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
research Progesterone-induced spike-wave discharges are inhibited by finasteride
Finasteride blocks progesterone's effect on brain activity linked to epilepsy.